NEW YORK (GenomeWeb) – Exact Sciences reported after the close of the market on Thursday that its first quarter revenues rose 87 percent year over year, thanks to a corresponding 87 percent increase in testing volumes for its Cologuard noninvasive colon cancer screening test.

For the three months ended March 31, the molecular diagnostics company reported revenues of $90.3 million, up from $48.4 million in Q1 2017, and beating analysts' average estimate of $86.9 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.